Research programme: glycosylation inhibitors - Infinity Pharmaceuticals/Seikagaku

Drug Profile

Research programme: glycosylation inhibitors - Infinity Pharmaceuticals/Seikagaku

Latest Information Update: 16 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Infinity Pharmaceuticals; Seikagaku Corporation
  • Class
  • Mechanism of Action Glycosylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 31 Dec 2008 Discontinued - Preclinical for Undefined indication in Japan (unspecified route)
  • 13 Sep 2006 Discovery Partners International has been acquired and merged into Infinity Pharmaceuticals
  • 28 Nov 2005 Preclinical trials in Undefined in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top